References
- What is schizophrenia? | NAMI: National Alliance on Mental Illness [Internet]; [cited 2021 Jun 1]. Available from: https://www.nami.org/About-Mental-Illness/Mental-Health-Conditions/Schizophrenia/Overview
- McGrath J, Saha S, Chant D, et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30(1):67–76.
- Hollis C, Rapoport J. Child and adolescent schizophrenia. In: Weinberger D, Harrison P, editors. Schizophrenia. 3rd ed. Wiley-Blackwell; 2011. p. 24–46. Available from: https://doi.org/https://doi.org/10.1002/9781444327298.ch3
- NIMH. Schizophrenia [Internet]; [cited 2021 Jun 1]. Available from: https://www.nimh.nih.gov/health/statistics/schizophrenia
- Rössler W, Joachim Salize H, Van Os J, et al. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol. 2005;15(4):399–409.
- Desai PR, Lawson KA, Barner JC, et al. Estimating the direct and indirect costs for community-dwelling patients with schizophrenia. J Pharm Heal Serv Res. 2013;4(4):187–194.
- Huang A, Amos TB, Joshi K, et al. Understanding healthcare burden and treatment patterns among young adults with schizophrenia. J Med Econ. 2018;21(10):1026–1035.
- Cloutier M, Aigbogun MS, Guerin A, et al. The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry. 2016;77(6):764–771.
- Zur J, Musumeci M, Garfield R. Medicaid’s role in financing behavioral health services for low-income individuals; [Internet]; [cited 2021 Jun 1]. Available from: https://www.kff.org/medicaid/issue-brief/medicaids-role-in-financing-behavioral-health-services-for-low-income-individuals/
- Khaykin E, Eaton WW, Ford DE, et al. Health insurance coverage among persons with schizophrenia in the United States. Psychiatr Serv. 2010;61(8):830–834.
- Fitch K, Iwasaki K, Villa KF. Resource utilization and cost in a commercially insured population with schizophrenia. Am Health Drug Benefits. 2014;7:18–26.
- Health insurance coverage for children and young adults under 26 | HealthCare.gov [Internet]; 2021 [cited 2021 Jun 1]. Available from: https://www.healthcare.gov/young-adults/children-under-26/
- Busch SH, Golberstein E, Goldman HH, et al. Effects of ACA expansion of dependent coverage on hospital-based care of young adults with early psychosis. Psychiatr Serv. 2019;70(11):1027–1033.
- Pesa J, Rotter D, Papademetriou E, et al. Real world analysis of insurance churn among young adult patients with schizophrenia using the Colorado All Payer Claims Database (CO-APCD) | Psychiatry & Behavioral Health Learning Network. Psych Congr [Internet]. Virtual; 2020; [cited 2021 Jun 1]. Available from: https://www.psychcongress.com/posters/real-world-analysis-insurance-churn-among-young-adult-patients-schizophrenia-using-colorado
- What’s in the CO APCD? CIVHC.org [Internet]; 2021 [cited 2021 Jun 1]. Available from: https://www.civhc.org/get-data/whats-in-the-co-apcd/
- CO APCD Info – CIVHC.org [Internet]; 2021 [cited 2021 Jun 1]. Available from: https://www.civhc.org/get-data/co-apcd-info/
- Capabilities of the Colorado All Payer Claims Database Type of Information What You Can’t Do With Claims Alone What You Can’t Do With the CO APCD Currently* What You CAN Do With the CO APCD Right Now Claim Type and Specifics [Internet]. Cent. Improv. Value Heal. Care. Capab. Color. All Payer Claims Database; 2017 [cited 2021 Jun 1]. Available from: http://www.civhc.org/wp-content/uploads/2017/08/CO-APCD-Capabilities_Oct-2017_Final.pdf
- Colorado Health Institute. Colorado health access survey methodology report [Internet]; 2015 [cited 2021 Feb 23]. Available from: https://www.shadac.org/sites/default/files/CO_2015_HH_Methodology.pdf
- Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130–1139.
- Parsons LS. Performing a 1: N Case-Control Match on Propensity Score. SAS Conf Proc SAS Users Gr Int 29; [Internet]; 2004; Montreal: Paper 165-29. Available from: https://support.sas.com/resources/pap; https://support.sas.com/resources/papers/proceedings/proceedings/sugi29/165-29.pdf
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders [Internet]. American Psychiatric Association; 2013 [cited 2021 Jun 1]. Available from: https://doi.org/https://doi.org/10.1176/appi.books.9780890425596
- Hensel JM, Chartier MJ, Ekuma O, et al. Risk and associated factors for a future schizophrenia diagnosis after an index diagnosis of unspecified psychotic disorder: a population-based study. J Psychiatr Res. 2019;114:105–112.
- Wallace A, Barron J, York W, et al. Health care resource utilization and cost before initial schizophrenia diagnosis. J Manag Care Spec Pharm. 2019;1–10.
- Wallace A, Isenberg K, York W, et al. Detecting schizophrenia early: prediagnosis healthcare utilization characteristics of patients with schizophrenia may aid early detection. Schizophr Res. 2020;215:392–398.
- Rosen JL, Miller TJ, D'Andrea JT, et al. Comorbid diagnoses in patients meeting criteria for the schizophrenia prodrome. Schizophr Res. 2006;85(1–3):124–131.
- Öngür D, Lin L, Cohen BM. Clinical characteristics influencing age at onset in psychotic disorders. Compr Psychiatry. 2009;50(1):13–19.
- Chuma J, Mahadun P. Predicting the development of schizophrenia in high-risk populations: systematic review of the predictive validity of prodromal criteria. Br J Psychiatry. 2011;199(5):361–366.
- White T, Anjum A, Schulz SC. The schizophrenia prodrome. Am J Psychiatry. 2006;163(3):376–380.
- Buckley PF, Miller BJ, Lehrer DS, et al. Psychiatric comorbidities and schizophrenia. Schizophr Bull. 2009;35(2):383–402.
- Yeomans D, Taylor M, Currie A, et al. Resolution and remission in schizophrenia: getting well and staying well [Internet]. Advances in psychiatric treatment. Cambridge University Press; 2010 [cited 2021 Jun 1]. p. 86–95. Available from: https://www.cambridge.org/core/journals/advances-in-psychiatric-treatment/article/resolution-and-remission-in-schizophrenia-getting-well-and-staying-well/767E7B84B3EA3BDD8D81521EB80882E8
- Emsley R, Chiliza B, Asmal L, et al. The nature of relapse in schizophrenia. BMC Psychiatry. 2013;13:50.
- Alphs L, Nasrallah HA, Bossie CA, et al. Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy. Int Clin Psychopharmacol. 2016;31(4):202–209.
- Stevens GL, Dawson G, Zummo J. Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia. Early Interv Psychiatry. 2016;10(5):365–377.
- Brissos S, Veguilla MR, Taylor D, et al. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol. 2014;4(5):198–219.
- Kishimoto T, Hagi K, Kurokawa S, et al. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies. Lancet Psychiatry. 2021;8(5):387–404.
- Lin D, Thompson-Leduc P, Ghelerter I, et al. Real-world evidence of the clinical and economic impact of long-acting injectable versus oral antipsychotics among patients with schizophrenia in the United States: a systematic review and meta-analysis. CNS Drugs. 2021;35:469–481.
- De Berardis D, Marini S, Carano A, et al. Efficacy and safety of long acting injectable atypical antipsychotics: a review. Curr Clin Pharmacol. 2013;8(3):256–264.
- De Berardis D, Vellante F, Olivieri L, et al. The effect of paliperidone palmitate long-acting injectable (PP-LAI) on “non-core” symptoms of schizophrenia: a retrospective, collaborative, multicenter study in the “real world” everyday clinical practice. Riv Psichiatr. 2021;56(3):143–148.